The Novo Nordisk Foundation (NNF ... is the NIVI’s novel structure, combining a state-of-the-art research centre with a limited liability company, according to the NNF. That will help to ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
1don MSN
CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
The company behind popular weight-loss drugs failed to disclose even more money it paid to healthcare groups and patient organisations , a pharmaceutical watchdog has said. Novo Nordisk - which ...
Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback